دورية أكاديمية
أعرض في EDS

Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer.

التفاصيل البيبلوغرافية
العنوان: Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer.
المؤلفون: Al-Nakouzi N; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada. nalnakouzi@prostatecentre.com.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada. nalnakouzi@prostatecentre.com., Wang CK; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Oo HZ; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Nelepcu I; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Lallous N; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Spliid CB; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA., Khazamipour N; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Lo J; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Truong S; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Collins C; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Hui D; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Esfandnia S; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Adomat H; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Clausen TM; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA., Gustavsson T; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.; VAR2pharmaceuticals Ole Maaløes Vej 3, 2200, København, Denmark., Choudhary S; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.; VAR2pharmaceuticals Ole Maaløes Vej 3, 2200, København, Denmark., Dagil R; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.; VAR2pharmaceuticals Ole Maaløes Vej 3, 2200, København, Denmark., Corey E; Department of Urology, University of Washington, Seattle, WA, 98195, USA., Wang Y; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Chauchereau A; Prostate Cancer Group, INSERM UMR981, Gustave Roussy, University of Paris-Saclay, F-94805, Villejuif, France., Fazli L; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Esko JD; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA., Salanti A; Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark., Nelson PS; Department of Urology, University of Washington, Seattle, WA, 98195, USA.; Fred Hutchinson Cancer Centre, Seattle, WA, 98109-1024, USA., Gleave ME; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada., Daugaard M; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada. mads.daugaard@ubc.ca.; Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada. mads.daugaard@ubc.ca.
المصدر: Nature communications [Nat Commun] 2022 Aug 13; Vol. 13 (1), pp. 4760. Date of Electronic Publication: 2022 Aug 13.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy, Androgens ; Chondroitin Sulfates ; Glycocalyx/metabolism ; Humans ; Male ; Signal Transduction ; Tumor Microenvironment
مستخلص: Lineage plasticity of prostate cancer is associated with resistance to androgen receptor (AR) pathway inhibition (ARPI) and supported by a reactive tumor microenvironment. Here we show that changes in chondroitin sulfate (CS), a major glycosaminoglycan component of the tumor cell glycocalyx and extracellular matrix, is AR-regulated and promotes the adaptive progression of castration-resistant prostate cancer (CRPC) after ARPI. AR directly represses transcription of the 4-O-sulfotransferase gene CHST11 under basal androgen conditions, maintaining steady-state CS in prostate adenocarcinomas. When AR signaling is inhibited by ARPI or lost during progression to non-AR-driven CRPC as a consequence of lineage plasticity, CHST11 expression is unleashed, leading to elevated 4-O-sulfated chondroitin levels. Inhibition of the tumor cell CS glycocalyx delays CRPC progression, and impairs growth and motility of prostate cancer after ARPI. Thus, a reactive CS glycocalyx supports adaptive survival and treatment resistance after ARPI, representing a therapeutic opportunity in patients with advanced prostate cancer.
(© 2022. The Author(s).)
References: Biomed Res Int. 2014;2014:642798. (PMID: 24955366)
Nature. 2020 Aug;584(7822):535-546. (PMID: 32848221)
Sci Transl Med. 2014 Sep 3;6(252):252ra122. (PMID: 25186177)
Tumour Biol. 2015 Nov;36(11):9023-30. (PMID: 26084610)
Cancer Cell. 2020 Aug 10;38(2):279-296.e9. (PMID: 32679108)
Int J Appl Basic Med Res. 2018 Oct-Dec;8(4):203. (PMID: 30598904)
Mol Endocrinol. 2013 Dec;27(12):2028-40. (PMID: 24109594)
Cancer Cell. 2017 Oct 9;32(4):474-489.e6. (PMID: 29017058)
Nature. 2018 Jul;559(7714):363-369. (PMID: 29950727)
Curr Oncol Rep. 2017 May;19(5):32. (PMID: 28361223)
Prostate Cancer Prostatic Dis. 2013 Sep;16(3):277-84. (PMID: 23835622)
N Engl J Med. 2013 Jan 10;368(2):138-48. (PMID: 23228172)
Clin Cancer Res. 2013 Jul 1;19(13):3621-30. (PMID: 23649003)
Biochim Biophys Acta. 2013 Oct;1830(10):4719-33. (PMID: 23774590)
Oncogene. 2002 Jul 18;21(31):4739-46. (PMID: 12101412)
Clin Biochem Rev. 2016 Feb;37(1):3-15. (PMID: 27057074)
J Biol Chem. 2001 Sep 28;276(39):36344-53. (PMID: 11470797)
Oncogene. 2012 Mar 1;31(9):1130-42. (PMID: 21804603)
Nat Cell Biol. 2018 Oct;20(10):1203-1214. (PMID: 30202050)
Nature. 2001 May 17;411(6835):375-9. (PMID: 11357145)
Eur Urol. 2017 Jul;72(1):142-150. (PMID: 28408175)
Cancer Cell. 2011 Oct 18;20(4):457-71. (PMID: 22014572)
J Biol Chem. 2009 Jun 19;284(25):16832-16839. (PMID: 19346253)
N Engl J Med. 2019 Jul 11;381(2):121-131. (PMID: 31157964)
EMBO Mol Med. 2016 Jul 01;8(7):761-78. (PMID: 27198502)
EMBO J. 2015 Feb 12;34(4):502-16. (PMID: 25535248)
J Biol Chem. 2003 Sep 19;278(38):36115-27. (PMID: 12847091)
Genome Biol. 2014 Aug 26;15(8):426. (PMID: 25155515)
Mol Cancer Ther. 2004 Aug;3(8):921-32. (PMID: 15299075)
Cancer Metastasis Rev. 2014 Sep;33(2-3):399-411. (PMID: 24425228)
Nat Rev Cancer. 2015 Dec;15(12):701-11. (PMID: 26563462)
Nat Commun. 2016 Apr 26;7:11312. (PMID: 27115988)
Elife. 2017 Dec 21;6:. (PMID: 29266001)
Sci Rep. 2020 Dec 10;10(1):21750. (PMID: 33303959)
Clin Cancer Res. 1998 Apr;4(4):963-71. (PMID: 9563891)
Cell Death Discov. 2020 Jul 27;6:65. (PMID: 32793395)
Oncogene. 2013 Dec 5;32(49):5501-11. (PMID: 23752182)
J Pathol. 2008 Jun;215(2):118-25. (PMID: 18338334)
Cell Rep. 2015 Aug 11;12(6):922-36. (PMID: 26235627)
Elife. 2019 Sep 03;8:. (PMID: 31478829)
J Intern Med. 2016 Jul;280(1):97-113. (PMID: 26749537)
Cancer Cell. 2017 Mar 13;31(3):368-382. (PMID: 28292438)
Clin Cancer Res. 2014 Jun 1;20(11):2846-50. (PMID: 24727321)
Oncotarget. 2015 Jan 30;6(3):1806-20. (PMID: 25544761)
Endocrinology. 2006 Jan;147(1):590-8. (PMID: 16210365)
N Engl J Med. 2014 Jul 31;371(5):424-33. (PMID: 24881730)
Int J Biol Sci. 2014 Jun 01;10(6):588-95. (PMID: 24948871)
Nat Rev Urol. 2010 Sep;7(9):494-509. (PMID: 20818327)
Mol Cancer Res. 2016 Dec;14(12):1288-1299. (PMID: 27655130)
N Engl J Med. 2011 May 26;364(21):1995-2005. (PMID: 21612468)
Cancer Cell. 2015 Oct 12;28(4):500-514. (PMID: 26461094)
Cancer Res. 2001 Feb 15;61(4):1686-92. (PMID: 11245484)
Nat Commun. 2018 Aug 16;9(1):3279. (PMID: 30115931)
Methods Mol Biol. 2009;498:91-103. (PMID: 18988020)
Nat Commun. 2017 Sep 4;8(1):420. (PMID: 28871082)
Nature. 2014 Jul 17;511(7509):319-25. (PMID: 25030168)
Science. 2017 Jan 6;355(6320):84-88. (PMID: 28059768)
Cancer Biomark. 2017 Dec 12;21(1):229-234. (PMID: 29081414)
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14846-51. (PMID: 14657396)
Lancet Oncol. 2019 May;20(5):686-700. (PMID: 30987939)
Int J Mol Sci. 2019 Mar 19;20(6):. (PMID: 30893936)
Rev Urol. 2007;9 Suppl 1:S3-8. (PMID: 17387371)
EMBO J. 2019 Jun 3;38(11):. (PMID: 31000523)
Biochem J. 2010 Jan 15;425(3):575-83. (PMID: 19886863)
Cancer Cell. 2014 Jul 14;26(1):121-135. (PMID: 25002027)
Lancet. 2018 Dec 1;392(10162):2353-2366. (PMID: 30355464)
Lancet Oncol. 2018 Feb;19(2):194-206. (PMID: 29326030)
Bioconjug Chem. 2010 Oct 20;21(10):1912-6. (PMID: 20886827)
J Urol. 1984 May;131(5):1008-12. (PMID: 6200616)
Nat Rev Urol. 2012 Feb 21;9(4):196-206. (PMID: 22349653)
FEBS J. 2019 May;286(10):1815-1837. (PMID: 30637950)
J Biol Chem. 2008 Nov 28;283(48):33674-84. (PMID: 18818196)
Front Oncol. 2019 Aug 28;9:801. (PMID: 31555580)
EMBO J. 2012 Jun 13;31(12):2810-23. (PMID: 22531786)
J Clin Oncol. 2002 Jul 15;20(14):3072-80. (PMID: 12118020)
Cancer Discov. 2017 Jan;7(1):54-71. (PMID: 27784708)
Sci Rep. 2020 Jul 9;10(1):11262. (PMID: 32647242)
Endocr Relat Cancer. 2017 Mar;24(3):R49-R64. (PMID: 28159857)
J Neurosci Methods. 2011 Sep 30;201(1):228-38. (PMID: 21855577)
Sci Rep. 2019 Sep 24;9(1):13786. (PMID: 31551480)
Cancer Res. 2003 Aug 15;63(16):4786-91. (PMID: 12941795)
Nat Rev Urol. 2019 Nov;16(11):645-654. (PMID: 31591549)
Exp Cell Res. 2011 Feb 1;317(3):262-75. (PMID: 20974126)
Cell. 2019 Jun 13;177(7):1757-1770.e21. (PMID: 31056282)
معلومات مُعتمدة: P50 CA097186 United States CA NCI NIH HHS; PJT-153092 Canada CIHR
المشرفين على المادة: 0 (Androgens)
9007-28-7 (Chondroitin Sulfates)
تواريخ الأحداث: Date Created: 20220813 Date Completed: 20220816 Latest Revision: 20220908
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9376089
DOI: 10.1038/s41467-022-32530-7
PMID: 35963852
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا